Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the first quarter of 2024.
- First-quarter revenue was $1.62 billion, which is up 5% on a reported basis and 7% at constant currency
- Women’s Health revenue increased by 11% and Biosimilars revenue climbed by 46%
- Meanwhile, Established Brands revenue was flat on an as-reported basis during the quarter
- Reported earnings per share and adjusted earnings per share were $0.78 and $1.22, respectively, during the three months
- Net income came in at $201 million in the March quarter and adjusted EBITDA was $538 million
- Gross margin was 59.0% on a reported basis and 62.1% on an adjusted basis in the first quarter
- Adjusted EBITDA margin dropped to 33.2% in the first quarter from 33.7% last year
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
